ARTL — Artelo Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Artelo Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 August 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.44 | -10.1 | -9.29 | -9.83 | -12.9 |
| Non-Cash Items | 1.54 | 2.29 | 0.419 | 0.569 | 2.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.244 | -0.215 | 0.663 | 0.907 | 1.75 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -6.14 | -8.01 | -8.21 | -8.35 | -8.52 |
| Capital Expenditures | — | — | — | — | -0.25 |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -3.44 | 2.96 | 3.51 | 7.77 | 0.188 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.44 | 2.96 | 3.51 | 7.77 | -0.062 |
| Financing Cash Flow Items | -0.007 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.1 | 0 | 0.567 | 0.112 | 6.87 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.49 | -5.27 | -4.07 | -0.477 | -1.74 |